Últimas noticias sobre PTC Therapeutics (NASDAQ:PTCT) Bolsa

PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics Inc

Baird analyst Joel Beatty reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and maintains $44 price target.

News

Price Target

Reiteration

Analyst Ratings

PTCT

Baird Reiterates Outperform on PTC Therapeutics, Maintains $44 Price Target

WIIM

PTC Therapeutics shares are trading higher after the company announced its Vatiquinone Friedreich Ataxia program met its endpoint for two FA long-term extension studies. Also, PTC has recently aligned with the FDA on key aspects of the planned NDA submission.

PTC Therapeutics Announces Updates On Vatiquinone Friedreich Ataxia Program; Says Pre-Specified Endpoint For Two FA Long-Term Extension Studies Was Met, Says Co. Recently Aligned With FDA On Key Aspects On Planned NDA Submission

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Sector Perform and raises the price target from $32 to $34.

RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $34

Biotech

General

PTC Therapeutics Announces FDA Acceptance For Filing Of NDA For Sepiapterin For Pediatric And Adult Phenylketonuria Patients

FDA Grants Fast Track Designation To PTC Therapeutics' PTC518 Program For Huntington's Disease, Highlighting Its Potential As A Disease-Modifying Therapy

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and maintains $64 price target.

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target

Baird analyst Joel Beatty initiates coverage on PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform rating and announces Price Target of $44.

Initiation

Baird Initiates Coverage On PTC Therapeutics with Outperform Rating, Announces Price Target of $44

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $62 to $64.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $64

Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $25 to $31.

Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $31

PTC Updates Full Year 2024 Financial Guidance:&nbsp;
<ul>
<li>PTC anticipates total revenues for full year 2024 to be between $700 million and $750 million.</li>
<li>PTC anticipates GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $740 million and $835 million, including expected R&amp;D expense milestone payments of up to $65 million.</li>
<li>PTC anticipates Non-GAAP R&amp;D and SG&amp;A expenses for full year 2024 to be between $660 million and $755 million, including expected R&amp;D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.</li>
<li>PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&amp;D operating expenses. As of June 30, 2024, $35 million in milestones have been achieved, of which $15 million has been recorded as R&amp;D operating expenses and $20 million as contingent consideration payable.</li>
</ul>

Guidance

PTC Sees FY24 Revenue $700M-$750M Vs $749M Estimate

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.19) by 8.4 percent. The company reported quarterly sales of $186.704 million which beat the analyst consensus estimate of $185.319 million by 0.75 percent. This is a 12.68 percent decrease over sales of $213.808 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

PTC Therapeutics Q2 2024 GAAP EPS $(1.29) Misses $(1.19) Estimate, Sales $186.704M Beat $185.319M Estimate

PTC Therapeutics Submits Sepiapterin NDA To FDA For Treatment Of Pediatric And Adult Phenylketonuria (PKU) Patients

Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and maintains $62 price target.

Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $62 Price Target

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and raises the price target from $30 to $32.

Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $32

PTC Therapeutics shares are trading higher following a report suggesting that the company requested a re-examination of the EMA's June 2024 opinion.

Global

EMA Says Company For Translarna Has Requested A Re-Examination Of EMA's June 2024 Opinion

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $52 to $62.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $62

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price target of $...

Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)

PTC Therapeutics Huntington's disease candidate nabs FDA Fast Track status

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating on September 16. Joel Beatty has given h...

Positive Outlook on PTC Therapeutics: Buy Rating Backed by Fast Track Designation and Promising Clinical Trials

PTC Therapeutics brain disorder therapy granted FDA review

William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on September 26. Sami Corwin has given his...

Buy Rating Affirmed for PTC Therapeutics on Sepiapterin's Strong Regulatory and Clinical Prospects for PKU Treatment

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Buy Rating on PTC Therapeutics' Vatiquinone for Friedreich Ataxia Supported by Promising Trial Results and Regulatory Pathway

PTC Therapeutics sees positive long-term results on vatiquinone for Friedreich ataxia

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating today. Joel Beatty's rating is based on ...

Positive Clinical Trials and FDA Advancements Bolster Buy Rating for PTC Therapeutics

BIIB

LRMR

LXEO

Press Releases

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Comments

PTC Therapeutics

Noticias

Últimas noticias sobre PTC Therapeutics (NASDAQ:PTCT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL